MCID: LTR001
MIFTS: 54

Lateral Sclerosis

Categories: Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Lateral Sclerosis

MalaCards integrated aliases for Lateral Sclerosis:

Name: Lateral Sclerosis 12 15 71
Primary Lateral Sclerosis 12 74 52 53
Adult-Onset Primary Lateral Sclerosis 12 52
Motor Neuron Disease 43 71
Adult-Onset Pls 52

Classifications:



External Ids:

Disease Ontology 12 DOID:230
ICD9CM 34 335.24
MeSH 43 D016472
NCIt 49 C129933
SNOMED-CT 67 81211007
ICD10 32 G12.23
UMLS 71 C0085084 C0154682

Summaries for Lateral Sclerosis

NIH Rare Diseases : 52 Primary lateral sclerosis (PLS) is a rare neuromuscular disease that affects the nerve cells that control the voluntary muscles. Problems in the legs (such as weakness, stiffness, spasticity , and balance problems) are often observed first, but hand clumsiness and changes in speech can be early symptoms, as well. The condition is progressive (gradually becomes worse over time); however, affected people have a normal life expectancy. The underlying cause of adult PLS is currently unknown. In most cases, it occurs sporadically in people with no family history of the condition. A subtype of PLS, called juvenile PLS , is caused by changes (mutations ) in the ALS2 gene and is inherited in an autosomal recessive manner. Treatment is based on the signs and symptoms present in each person.

MalaCards based summary : Lateral Sclerosis, also known as primary lateral sclerosis, is related to primary lateral sclerosis, adult, 1 and frontotemporal dementia and/or amyotrophic lateral sclerosis 3, and has symptoms including ataxia, myoclonus and hemiplegia. An important gene associated with Lateral Sclerosis is SOD1 (Superoxide Dismutase 1), and among its related pathways/superpathways are Neuroscience and Cytoskeleton remodeling Neurofilaments. The drugs Mexiletine and Minocycline have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and cortex, and related phenotypes are behavior/neurological and cellular

Disease Ontology : 12 A motor neuron disease characterized by painless but progressive weakness and stiffness of the muscles of the legs.

Wikipedia : 74 Primary lateral sclerosis (PLS) is a very rare neuromuscular disease characterized by progressive muscle... more...

Related Diseases for Lateral Sclerosis

Diseases in the Lateral Sclerosis family:

Primary Lateral Sclerosis, Juvenile Primary Lateral Sclerosis, Adult, 1

Diseases related to Lateral Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 928)
# Related Disease Score Top Affiliating Genes
1 primary lateral sclerosis, adult, 1 35.1 SOD1 ALS2
2 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 34.9 TARDBP PRPH C9orf72
3 frontotemporal dementia and/or amyotrophic lateral sclerosis 4 34.8 TARDBP PRPH
4 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 34.8 TRPM7 TARDBP SOD1 C9orf72
5 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 34.8 PRPH MATR3 CHCHD10 C9orf72
6 amyotrophic lateral sclerosis type 22 34.8 TARDBP PRPH C9orf72
7 amyotrophic lateral sclerosis type 5 34.7 VAPB SPG11 SOD1 SETX ALS2
8 amyotrophic lateral sclerosis 7 34.6 VAPB SPG11 SETX PRPH ALS2
9 amyotrophic lateral sclerosis 12 34.6 VAPB TARDBP SPG11 SOD1 SETX FUS
10 amyotrophic lateral sclerosis 11 34.6 VAPB TARDBP SPG11 SIGMAR1 SETX FUS
11 amyotrophic lateral sclerosis 19 34.6 UBQLN2 TARDBP SOD1 PRPH MATR3 ALS2
12 amyotrophic lateral sclerosis 18 34.5 VAPB UBQLN2 SIGMAR1 SETX PRPH FUS
13 amyotrophic lateral sclerosis 21 34.4 VAPB SPG11 SETX PRPH MATR3 FUS
14 amyotrophic lateral sclerosis 17 34.4 VAPB UBQLN2 SPG11 SIGMAR1 SETX PRPH
15 c9orf72-related amyotrophic lateral sclerosis and frontotemporal dementia 34.4 LOC109504728 C9orf72
16 amyotrophic lateral sclerosis 9 34.4 VAPB UBQLN2 SPG11 SOD1 SIGMAR1 SETX
17 amyotrophic lateral sclerosis 20 34.4 VAPB SPG11 SOD1 PRPH MATR3 HNRNPA1
18 amyotrophic lateral sclerosis 4, juvenile 34.4 VAPB UBQLN2 TARDBP SPG11 SOD1 SETX
19 juvenile amyotrophic lateral sclerosis 34.3 TRPM7 SPG11 SIGMAR1 SETX FUS ALS2
20 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.2 VAPB UBQLN2 TARDBP SPG11 SOD1 SETX
21 amyotrophic lateral sclerosis type 6 34.1 VAPB UBQLN2 TARDBP SPG11 SOD1 SIGMAR1
22 amyotrophic lateral sclerosis 16, juvenile 34.0 VCP VAPB UBQLN2 SPG11 SIGMAR1 SETX
23 amyotrophic lateral sclerosis 8 34.0 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
24 amyotrophic lateral sclerosis type 15 34.0 VAPB UBQLN2 SPG11 SIGMAR1 SETX PRPH
25 amyotrophic lateral sclerosis type 14 33.9 VCP VAPB UBQLN2 SPG11 SIGMAR1 SETX
26 spinal muscular atrophy, distal, autosomal recessive, 4 33.8 SPG11 ALS2
27 neuronopathy, distal hereditary motor, type viib 33.6 TARDBP DCTN1 ALS2
28 inclusion body myopathy with early-onset paget disease with or without frontotemporal dementia 1 33.4 VCP HNRNPA1
29 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 33.3 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
30 spinocerebellar ataxia 2 33.2 VAPB UBQLN2 TARDBP SPG11 SOD1 SETX
31 inclusion body myopathy with paget disease of bone and frontotemporal dementia 33.1 VCP UBQLN2 TARDBP HNRNPA1 FUS C9orf72
32 amyotrophic lateral sclerosis 1 33.1 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
33 perry syndrome 33.0 VCP TARDBP DCTN1 C9orf72
34 proximal spinal muscular atrophy 32.9 VAPB SETX
35 frontotemporal dementia 32.8 VCP UBQLN2 TARDBP SOD1 NEFH LOC109504728
36 progressive muscular atrophy 32.7 VCP VAPB UBQLN2 TARDBP SOD1 FUS
37 progressive bulbar palsy 32.6 VAPB SOD1 NEFH FUS C9orf72 ALS2
38 neuromuscular disease 32.6 VCP SOD1 NEFH FUS DCTN1 C9orf72
39 multisystem proteinopathy 32.5 VCP UBQLN2 TARDBP MATR3 HNRNPA1 FUS
40 motor neuron disease 32.5 VCP VAPB TARDBP SOD1 SIGMAR1 SETX
41 distal hereditary motor neuropathies 32.3 SETX DCTN1
42 aphasia 31.3 VCP TARDBP FUS C9orf72
43 muscular atrophy 31.2 VAPB TARDBP SIGMAR1 SETX HNRNPA1 FUS
44 supranuclear palsy, progressive, 1 31.1 VCP TARDBP SOD1 FUS DCTN1 C9orf72
45 semantic dementia 31.0 TARDBP C9orf72
46 progressive non-fluent aphasia 30.9 VCP C9orf72
47 agraphia 30.9 VCP TARDBP C9orf72
48 dysgraphia 30.9 TARDBP C9orf72
49 movement disease 30.9 TARDBP FUS C9orf72
50 autosomal dominant cerebellar ataxia 30.9 VCP TARDBP SOD1 SETX FUS C9orf72

Graphical network of the top 20 diseases related to Lateral Sclerosis:



Diseases related to Lateral Sclerosis

Symptoms & Phenotypes for Lateral Sclerosis

UMLS symptoms related to Lateral Sclerosis:


ataxia, myoclonus, hemiplegia, muscular fasciculation

MGI Mouse Phenotypes related to Lateral Sclerosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.07 ALS2 C9orf72 CHCHD10 DCTN1 NEFH RNF19A
2 cellular MP:0005384 9.97 C9orf72 CHCHD10 DCTN1 MATR3 NEFH RNF19A
3 muscle MP:0005369 9.5 ALS2 CHCHD10 DCTN1 SOD1 TARDBP VAPB
4 nervous system MP:0003631 9.44 ALS2 C9orf72 CHCHD10 DCTN1 NEFH PRPH

Drugs & Therapeutics for Lateral Sclerosis

Drugs for Lateral Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 346)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mexiletine Approved, Investigational Phase 4 31828-71-4 4178
2
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
3
Capsaicin Approved Phase 4 404-86-4 1548943
4 Anti-Inflammatory Agents Phase 4
5 Dermatologic Agents Phase 4
6 TA 0910 Phase 4
7
Olanzapine Approved, Investigational Phase 2, Phase 3 132539-06-1 4585
8
tannic acid Approved Phase 2, Phase 3 1401-55-4
9
Benzocaine Approved, Investigational Phase 2, Phase 3 94-09-7, 1994-09-7 2337
10
Methylcobalamin Approved, Investigational Phase 2, Phase 3 13422-55-4
11
Sargramostim Approved, Investigational Phase 2, Phase 3 83869-56-1, 123774-72-1
12
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
13
Quinidine Approved, Investigational Phase 3 56-54-2 441074
14
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
15
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 15589840 11953898
16
Acetylcholine Approved, Investigational Phase 2, Phase 3 51-84-3 187
17
Ethanol Approved Phase 3 64-17-5 702
18
Citalopram Approved Phase 3 59729-33-8 2771
19
Mecasermin Approved, Investigational Phase 3 68562-41-4
20
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
21
Ceftriaxone Approved Phase 3 73384-59-5 5361919 5479530
22
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
23
Memantine Approved, Investigational Phase 2, Phase 3 19982-08-2 4054
24
Edaravone Approved, Investigational Phase 3 89-25-8 70335
25
Ravulizumab Approved, Investigational Phase 3 1803171-55-2
26
Iron Approved, Experimental Phase 2, Phase 3 15438-31-0, 7439-89-6 27284 23925
27
Deferiprone Approved Phase 2, Phase 3 30652-11-0 2972
28
Trazodone Approved, Investigational Phase 2, Phase 3 19794-93-5 5533
29
Sodium citrate Approved, Investigational Phase 3 68-04-2
30
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
31
Riluzole Approved, Investigational Phase 3 1744-22-5 5070
32
Pramipexole Approved, Investigational Phase 3 104632-26-0 119570 59868
33
Lithium carbonate Approved Phase 2, Phase 3 554-13-2
34
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
35
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
36
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
37
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
38
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 3 303-98-0 5281915
39
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
40
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
41 Nabiximols Investigational Phase 2, Phase 3 56575-23-6
42 Molgramostim Investigational Phase 2, Phase 3 99283-10-0
43
Cobalamin Experimental Phase 2, Phase 3 13408-78-1 6857388
44
Tauroursodeoxycholic acid Experimental, Investigational Phase 3 14605-22-2 12443252
45
Simendan Investigational Phase 3 131741-08-7
46 retinol Phase 2, Phase 3
47 Retinol palmitate Phase 2, Phase 3
48 Adjuvants, Immunologic Phase 2, Phase 3
49 Quinidine gluconate Phase 3
50 Diuretics, Potassium Sparing Phase 3

Interventional clinical trials:

(show top 50) (show all 656)
# Name Status NCT ID Phase Drugs
1 Role of Non-invasive Ventilation in Amyotrophic Lateral Sclerosis: Volume Versus Pressure Mode Unknown status NCT00560287 Phase 4
2 Care (Canadian ALS Riluzole Evaluation) Multicentre Phase IV Comparative Study of the Effects of Riluzole 50mg Bid on the Survival of ALS Subjects Compared to Historical Controls Completed NCT00542412 Phase 4 Riluzole
3 Mexiletine for the Treatment of Muscle Cramps in ALS Completed NCT01811355 Phase 4 Mexiletine;Placebo
4 Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) Completed NCT00613899 Phase 4
5 Modafinil for Treatment of Fatigue in ALS Patients: Pilot Study Completed NCT00614926 Phase 4 Modafinil;Placebo
6 Riluzole in Fragile X Syndrome: A Pilot Study Incorporating Biomarker Assay Completed NCT00895752 Phase 4 Riluzole
7 Treatment of Childhood Regressive Autism With Minocycline: an Anti-Inflammatory Agent Active Within the CNS Completed NCT00409747 Phase 4 Minocycline
8 Evaluation of Motor Unit Abnormalities After Experimentally Induced Sensitization Using Capsaicin: A Randomized, Double-Blinded, Placebo-Controlled Study Completed NCT04361149 Phase 4 Capsaicin Topical Cream (0.075%)
9 Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IV Clinical Trial to Evaluate and Compare the Safety and Efficacy of C-Trelin OD Tab 5mg(Taltirelin Hydrate) in Patients With Ataxia Induced by Spinocerebellar Degeneration Recruiting NCT04107740 Phase 4 C-Trelin OD Tab(5mg Taltirelin Hydrate);Placebo
10 Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study Unknown status NCT03548311 Phase 3 methylcobalamin;saline solution
11 A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis Unknown status NCT00069186 Phase 3 Creatine Monohydrate
12 Randomized, Placebo-controlled Parallel Group Study for the Evaluation of an Oral Dose of 10mg Olanzapine in Combination With Riluzole for the Treatment of Loss of Appetite in Patients With Amyotrophic Lateral Sclerosis (ALS) Unknown status NCT00876772 Phase 2, Phase 3 Olanzapine
13 Phase 2/3 Application of Botulinum Neurotoxin Type A in Salivary Glands as a Treatment of Chronic Drooling in Patients With Cerebral Palsy: A Controlled Clinical Trial. Unknown status NCT01489904 Phase 2, Phase 3
14 A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients Completed NCT01776970 Phase 2, Phase 3 Cannabis Sativa extract Oromucosal spray
15 A Long-Term Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00445172 Phase 2, Phase 3 E0302 (mecobalamin)
16 The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013 Completed NCT01825551 Phase 2, Phase 3 Granulocyte Colony Stimulating Factor;Placebo
17 Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT01933321 Phase 2, Phase 3
18 A Double-Blind Controlled, Multicenter Phase II/III Study to Assess the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect in Patients With Amyotrophic Lateral Sclerosis Completed NCT00021697 Phase 3 AVP-923
19 A Phase II/III Study in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00444613 Phase 2, Phase 3 E0302 (mecobalamin);E0302 (mecobalamin);Placebo
20 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of Dexpramipexole in Subjects With Amyotrophic Lateral Sclerosis Completed NCT01281189 Phase 3 Dexpramipexole;Placebo
21 Phase 2-3 - Memantine for Disability in Amyotrophic Lateral Sclerosis Completed NCT00353665 Phase 2, Phase 3 Memantine (Ebixa);riluzole;Placebo
22 A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of Botulinum Toxin Type B (Myobloc) in Sialorrhea in Amyotrophic Lateral Sclerosis Completed NCT00125203 Phase 2, Phase 3 Botulinum toxin type B (Myobloc)
23 Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib Completed NCT02588677 Phase 2, Phase 3 Masitinib (4.5);Riluzole;Placebo;Masitinib (3.0)
24 An Expanded Controlled Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-Blind, Parallel-Group, Placebo-Controlled Manner (Phase 3) Completed NCT00424463 Phase 3 MCI-186;Placebo of MCI-186
25 An Exploratory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (Severity Classification III) in Double-Blind, Parallel-Group, Placebo-Controlled Manner Completed NCT00415519 Phase 3 MCI-186;Placebo of MCI-186
26 A Confirmatory Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis in Double-blind, Parallel-group, Placebo-controlled Manner. Completed NCT00330681 Phase 3 MCI-186;Placebo of MCI-186
27 An Open-label, 8- Week, Flexible Dose Trial of Escitalopram (Lexapro®) in Comorbid Major Depression With Amyotrophic Lateral Sclerosis and Multiple Sclerosis Completed NCT00965497 Phase 3 escitalopram
28 An Open-label Safety Extension Study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT01285583 Phase 2, Phase 3 TRO19622
29 Efficacy and Safety Study of MCI-186 for Treatment of the Patients With Amyotrophic Lateral Sclerosis (ALS) 2 Completed NCT01492686 Phase 3 MCI-186;Placebo;MCI-186 in open label phase
30 A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031) Completed NCT02936635 Phase 3 tirasemtiv
31 Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Completed NCT00035815 Phase 3 Insulin like growth factor, type 1;Placebo
32 Noninvasive Ventilation in ALS Patients With Mild Respiratory Involvement Completed NCT00386464 Phase 2, Phase 3
33 Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. Completed NCT00372879 Phase 3
34 A Randomized, Double-Blind, Placebo-Controlled Sequential Clinical Trial of Sodium Valproate in ALS Completed NCT00136110 Phase 3 Sodium Valproate
35 Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS Completed NCT03127514 Phase 2, Phase 3 AMX0035
36 Phase II/III, Multicenter, Randomized, Parallel Group, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) Patients Treated With Riluzole Completed NCT00868166 Phase 3 Olesoxime;Placebo Comparator;Riluzole
37 Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls. Analysis With 123I-FP-CIT (Datscan) and 123I-ADAM Brain SPECT Completed NCT01160263 Phase 3 SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM
38 A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy Completed NCT01951924 Phase 3 Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL);Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)
39 Minocycline to Treat Amyotrophic Lateral Sclerosis Completed NCT00047723 Phase 3 minocycline
40 Phase II/III Randomized, Placebo-Controlled Trial of Arimoclomol in SOD1 Positive Familial Amyotrophic Lateral Sclerosis (ALS) Completed NCT00706147 Phase 2, Phase 3 Arimoclomol;Placebo
41 Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS) Completed NCT00349622 Phase 3 ceftriaxone
42 A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Completed NCT02496767 Phase 3 Tirasemtiv;Placebo tablets
43 Repetitive Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis Completed NCT00833820 Phase 2, Phase 3
44 A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects Completed NCT01994109 Phase 3 MYOBLOC
45 A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS) Completed NCT00573443 Phase 3 dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;Placebo
46 Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study Completed NCT01257828 Phase 3 riluzole;Placebo medication
47 Double-Blind, Randomised, Two-Armed Study for the Evaluation of Efficacy and Safety of Minocycline for Treatment Completed NCT00146809 Phase 3 Minocyline
48 Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia Completed NCT02350127 Phase 2, Phase 3
49 A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone on Quality of Life as Measured by the Multiple Sclerosis Quality of Life Inventory (MSQLI54) Completed NCT00501696 Phase 3 4.5 mg Naltrexone;Naltrexone
50 A Double Blind Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia Completed NCT00733057 Phase 3 Minocycline;Placebo (200 mg/day)

Search NIH Clinical Center for Lateral Sclerosis

Cochrane evidence based reviews: motor neuron disease

Genetic Tests for Lateral Sclerosis

Anatomical Context for Lateral Sclerosis

MalaCards organs/tissues related to Lateral Sclerosis:

40
Brain, Spinal Cord, Cortex, Testes, Bone, Skeletal Muscle, Skin

Publications for Lateral Sclerosis

Articles related to Lateral Sclerosis:

(show top 50) (show all 23063)
# Title Authors PMID Year
1
Dermic-derived fibroblasts for the study of amyotrophic lateral sclerosis. 61
32394958 2020
2
New insights into Wnt signaling alterations in amyotrophic lateral sclerosis: a potential therapeutic target? 61
32209757 2020
3
Understanding metabolic flexibility: a potential key to unlocking metabolic therapies in amyotrophic lateral sclerosis? 61
32209766 2020
4
Dynamic changes and mislocalizations of neurodegenerative disease-related proteins in mice stroke model. 61
32360098 2020
5
Analysis of shared common genetic risk between amyotrophic lateral sclerosis and epilepsy. 61
32409253 2020
6
Importance of the serum biochemical parameters as potential biomarkers for rapid diagnosis and evaluating preclinical stage of ALS. 61
32315925 2020
7
Synaptic restoration by cAMP/PKA drives activity-dependent neuroprotection to motoneurons in ALS. 61
32484501 2020
8
The vulnerability of motor and frontal cortex-dependent behaviors in mice expressing ALS-linked mutation in TDP-43. 61
32422502 2020
9
Ubiquitin biology in neurodegenerative disorders: From impairment to therapeutic strategies. 61
32407951 2020
10
miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis. 61
32335272 2020
11
Reply to: Amyotrophic lateral sclerosis with depression, cognitive impairment, and mortality. 61
32124429 2020
12
REM sleep physiology and selective neuronal vulnerability in amyotrophic lateral sclerosis. 61
32354769 2020
13
Progression of cognitive and behavioural impairment in early amyotrophic lateral sclerosis. 61
32404381 2020
14
SOD1 p.D12Y variant is associated with amyotrophic lateral sclerosis/distal myopathy spectrum. 61
32250500 2020
15
Life Course Adiposity and Amyotrophic Lateral Sclerosis: A Mendelian Randomization Study. 61
32372439 2020
16
Alcohol Drinking and Amyotrophic Lateral Sclerosis: An Instrumental Variable Causal Inference. 61
32196748 2020
17
A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. 61
32339966 2020
18
Paravertebral block for radiologically inserted gastrostomy tube placement in amyotrophic lateral sclerosis. 61
32297335 2020
19
Modification of non-invasive ventilation for the advanced amyotrophic lateral sclerosis patient during the COVID-19 pandemic - do it now. 61
32417612 2020
20
CAG repeats ≥ 34 in Ataxin-1 gene are associated with amyotrophic lateral sclerosis in a Brazilian cohort. 61
32339968 2020
21
The increase in CSF total protein and immunoglobulins in Chinese patients with sporadic amyotrophic lateral sclerosis: A retrospective study. 61
32388062 2020
22
Everyday life experiences of close relatives of people with amyotrophic lateral sclerosis receiving home mechanical ventilation-A qualitative study. 61
32159905 2020
23
Hippocampal synaptic dysfunction in the SOD1G93A mouse model of Amyotrophic Lateral Sclerosis: Reversal by adenosine A2AR blockade. 61
32311420 2020
24
The Occurrence of FUS Mutations in Pediatric Amyotrophic Lateral Sclerosis: A Case Report and Review of the Literature. 61
32281455 2020
25
Single-cell RNA-seq analysis of the brainstem of mutant SOD1 mice reveals perturbed cell types and pathways of amyotrophic lateral sclerosis. 61
32360664 2020
26
Human brain connectivity: Clinical applications for clinical neurophysiology. 61
32417703 2020
27
Laryngeal electromyography in amyotrophic lateral sclerosis. 61
32317399 2020
28
Astrocyte-derived extracellular vesicles: Neuroreparative properties and role in the pathogenesis of neurodegenerative disorders. 61
32289328 2020
29
Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries. 61
32350120 2020
30
Role of microRNAs in neurodegeneration induced by environmental neurotoxicants and aging. 61
32283224 2020
31
Ashwagandha in brain disorders: A review of recent developments. 61
32305638 2020
32
Inactivation of Hippo and cJun-N-terminal Kinase (JNK) signaling mitigate FUS mediated neurodegeneration in vivo. 61
32199908 2020
33
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules. 61
32315731 2020
34
Superiority of sonographic evaluation of contracted versus relaxed muscle thickness in motor neuron diseases. 61
32387966 2020
35
Multiple MuSK signaling pathways and the aging neuromuscular junction. 61
32353380 2020
36
Traffic jam at the nuclear pore: All roads lead to nucleocytoplasmic transport defects in ALS/FTD. 61
32179176 2020
37
Molecular analysis and clinical diversity of distal hereditary motor neuropathy. 61
32298515 2020
38
Multifunctional memantine nitrate significantly protects against glutamate-induced excitotoxicity via inhibiting calcium influx and attenuating PI3K/Akt/GSK3beta pathway. 61
32092300 2020
39
Oligogenicity, C9orf72 expansion, and variant severity in ALS. 61
32385536 2020
40
Amyotrophic lateral sclerosis with depression, cognitive impairment, and mortality. 61
32124428 2020
41
Reply to "Life Course Adiposity and Amyotrophic Lateral Sclerosis". 61
32374448 2020
42
ALS and Parkinson's disease genes CHCHD10 and CHCHD2 modify synaptic transcriptomes in human iPSC-derived motor neurons. 61
32437855 2020
43
Exploring the multimodal role of phytochemicals in the modulation of cellular signaling pathways to combat age-related neurodegeneration. 61
32464743 2020
44
Orexins role in neurodegenerative diseases: From pathogenesis to treatment. 61
32315694 2020
45
Understanding the role of social cognition in neurodegenerative Disease: A scoping review on an overlooked problem. 61
32389547 2020
46
Effects of exercise on sleep in neurodegenerative disease. 61
32243913 2020
47
Multiple Roles of Transforming Growth Factor Beta in Amyotrophic Lateral Sclerosis. 61
32560258 2020
48
Serum creatinine levels in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. 61
32564621 2020
49
MicroRNA-183-5p is stress-inducible and protects neurons against cell death in amyotrophic lateral sclerosis. 61
32558113 2020
50
What do we know about the variability in survival of patients with amyotrophic lateral sclerosis? 61
32569484 2020

Variations for Lateral Sclerosis

Expression for Lateral Sclerosis

Search GEO for disease gene expression data for Lateral Sclerosis.

Pathways for Lateral Sclerosis

Pathways related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.89 TARDBP SOD1 SIGMAR1 NEFH DCTN1
2
Show member pathways
11.37 PRPH NEFH DCTN1
3 10.9 SOD1 PRPH NEFH ALS2

GO Terms for Lateral Sclerosis

Cellular components related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 10.17 VCP UBQLN2 TARDBP SPG11 SOD1 SIGMAR1
2 cytoplasm GO:0005737 10.03 VCP VAPB UBQLN2 TARDBP SPG11 SOD1
3 cytoplasmic stress granule GO:0010494 9.43 VCP TARDBP C9orf72
4 growth cone GO:0030426 9.26 SIGMAR1 SETX C9orf72 ALS2
5 axon GO:0030424 9.17 SPG11 SETX PRPH NEFH DCTN1 C9orf72

Biological processes related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament cytoskeleton organization GO:0045104 9.26 PRPH NEFH
2 regulation of autophagosome assembly GO:2000785 9.16 UBQLN2 C9orf72
3 neurofilament cytoskeleton organization GO:0060052 8.96 SOD1 NEFH
4 maintenance of synapse structure GO:0099558 8.62 DCTN1 CHCHD10

Molecular functions related to Lateral Sclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 VCP TARDBP SOD1 SETX MATR3 FUS

Sources for Lateral Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....